SSY · Sunlink Health Systems Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q1 '23 | Q3 '23 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.32M | $7.93M | $7.92M | - | $7.46M | $8.51M | $8.55M | $11.53M | $14.39M | $11.04M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $319.0K | $324.0K | $313.0K | - | $342.0K | $318.0K | $300.0K | $414.0K | $387.0K | $368.0K |
| Operating Income | ($683.0K) | ($1.01M) | ($1.19M) | - | ($853.0K) | ($433.0K) | ($450.0K) | ($774.0K) | $2.04M | ($1.61M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | ($10.0K) | $3.0K | $2.0K | ($6.0K) | $1.0K | $0 |
| Net Income | ($671.0K) | ($1.34M) | ($549.0K) | - | ($1.40M) | ($3.08M) | ($1.34M) | ($762.0K) | $1.95M | ($1.56M) |
| EPS - Basic | ($0.09) | ($0.15) | ($0.08) | - | ($0.20) | ($0.44) | ($0.19) | ($0.10) | $0.28 | ($0.22) |
| EPS - Diluted | ($0.09) | ($0.15) | ($0.08) | - | ($0.20) | ($0.44) | ($0.13) | ($0.11) | $0.28 | ($0.22) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q1 '23 | Q3 '23 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.47M | $8.02M | $7.53M | $7.17M | $1.21M | $2.06M | $2.82M | $5.38M | $5.16M | $4.95M |
| Accounts Receivable | $2.94M | $2.83M | $3.01M | $3.37M | $3.08M | $3.06M | $2.76M | $4.39M | $4.47M | $4.69M |
| Inventory | $1.46M | $1.55M | $1.55M | $1.55M | $1.56M | $1.59M | $1.60M | $1.79M | $1.81M | $1.84M |
| Accounts Payable | $1.47M | $1.15M | $1.34M | $1.91M | $1.53M | $1.42M | $1.36M | $1.57M | $1.88M | $1.83M |
| Current Assets | $13.71M | $14.21M | $15.62M | $15.66M | $10.97M | $13.71M | $16.53M | $13.30M | $15.02M | $15.41M |
| Total Assets | $17.47M | $17.87M | $19.63M | $20.61M | $16.14M | $18.79M | $21.72M | $24.43M | $26.17M | $26.83M |
| Current Liabilities | $3.50M | $3.50M | $3.85M | $4.21M | $3.96M | $5.23M | $4.99M | $4.68M | $5.63M | $8.16M |
| Long-term Debt | - | - | - | - | - | $0 | - | $0 | $0 | $3.0K |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $13.41M | $14.08M | $15.42M | $15.97M | $11.61M | $13.00M | $16.08M | $18.80M | $19.56M | $17.61M |
| Retained Earnings | ($1.08M) | ($414.0K) | $929.0K | $1.48M | ($2.81M) | ($1.41M) | $1.66M | $4.43M | $5.19M | $3.24M |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q1 '23 | Q3 '23 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($915.0K) | - | - | - | ($1.14M) | - | - | ($1.27M) |
| Investing Cash Flow | - | - | $1.27M | - | - | - | ($524.0K) | - | - | ($562.0K) |
| Financing Cash Flow | - | - | $0 | - | - | - | ($5.0K) | - | - | ($10.0K) |
| CapEx | - | - | $191.0K | - | - | - | $476.0K | $374.0K | $527.0K | $624.0K |
| Free Cash Flow | - | - | ($1.11M) | - | - | - | ($1.61M) | - | - | ($1.90M) |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q2 '23 | Q1 '23 | Q3 '23 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -9.3% | -12.8% | -15.1% | - | -11.4% | -5.1% | -5.3% | -6.7% | 14.2% | -14.6% |
| EBITDA margin | -5.0% | -8.7% | -11.1% | - | -6.8% | -1.4% | -1.8% | -3.1% | 16.9% | -11.3% |
| Net margin | -9.2% | -16.9% | -6.9% | - | -18.7% | -36.1% | -15.7% | -6.6% | 13.6% | -14.1% |
| Free cash flow margin | - | - | -14.0% | - | - | - | -18.9% | - | - | -17.2% |
| FCF / Net income | - | - | 2.01 | - | - | - | 1.20 | - | - | 1.22 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.1% | - |
| Return on assets | -3.8% | -7.5% | -2.8% | - | -8.6% | -16.4% | -6.2% | -3.1% | 7.5% | -5.8% |
| Return on equity | -5.0% | -9.5% | -3.6% | - | -12.0% | -23.6% | -8.4% | -4.1% | 10.0% | -8.8% |
| Return on invested capital | - | - | - | - | - | -2.6% | - | -3.3% | 10.4% | -7.2% |
| Liquidity | ||||||||||
| Current ratio | 3.91 | 4.06 | 4.06 | 3.72 | 2.77 | 2.62 | 3.31 | 2.84 | 2.67 | 1.89 |
| Quick ratio | 3.50 | 3.62 | 3.65 | 3.35 | 2.38 | 2.32 | 2.99 | 2.46 | 2.35 | 1.66 |
| Cash ratio | 2.13 | 2.29 | 1.96 | 1.70 | 0.31 | 0.39 | 0.56 | 1.15 | 0.92 | 0.61 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.00 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.30 | 1.27 | 1.27 | 1.29 | 1.39 | 1.44 | 1.35 | 1.30 | 1.34 | 1.52 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.42 | 0.44 | 0.40 | - | 0.46 | 0.45 | 0.39 | 0.47 | 0.55 | 0.41 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 147d | 130d | 139d | - | 151d | 131d | 118d | 139d | 113d | 155d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -1.9% | - | -7.4% | - | -35.3% | -40.9% | -22.5% | 9.6% | 38.2% | 4.9% |
| Revenue CAGR (3y) | -11.4% | -18.0% | -9.0% | - | -8.6% | -12.7% | -9.8% | -3.1% | 0.4% | -2.9% |
| Revenue CAGR (5y) | -10.4% | -9.1% | -8.0% | - | -8.0% | -9.3% | -8.5% | -3.0% | 0.2% | -3.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 19.9% | - | -165.3% | - | -10.2% | - | 72.1% | 27.3% | - | -62.4% |
| Net income growth (YoY) | 51.9% | - | 59.2% | - | -83.2% | - | 13.7% | 23.0% | - | - |
| EPS growth (YoY) | 55.0% | - | 38.5% | - | -81.8% | - | 40.9% | 21.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | 91.3% | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | -3.2% | - |
| FCF growth (YoY) | - | - | 31.4% | - | - | - | 14.9% | - | - | -84.7% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 15.5% | -11.8% | -4.1% | 22.8% | -38.3% | -33.5% | -8.7% | -11.4% | -11.9% | -22.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-06-30.
Business segments
$47.95M totalPharmacy Segment$33.51M · 69.9%
Healthcare Services Segment$14.44M · 30.1%
Peer comparison
Same SIC group: Services-General Medical & Surgical Hospitals, NEC
Comparing SUNLINK HEALTH SYSTEMS INC against the 5 most active filers in the same SIC group.